|
1
|
Botteman MF, Pashos CL, Redaelli A, Laskin
B and Hauser R: The health economics of bladder cancer: a
comprehensive review of the published literature.
Pharmacoeconomics. 21:1315–1330. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Millan-Rodriguez F, Chechile-Toniolo G,
Salvador-Bayarri J, Palou J and Vicente-Rodriguez J: Multivariate
analysis of the prognostic factors of primary superficial bladder
cancer. J Urol. 163:73–78. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Donat SM: Evaluation and follow-up
strategies for superficial bladder cancer. Urol Clin North Am.
30:765–776. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Witjes JA and Hendricksen K: Intravesical
pharmacotherapy for non-muscle-invasive bladder cancer: a critical
analysis of currently available drugs, treatment schedules, and
long-term results. Eur Urol. 53:45–52. 2008. View Article : Google Scholar
|
|
5
|
Schwaibold HE, Sivalingam S, May F and
Hartung R: The value of a second transurethral resection for T1
bladder cancer. BJU Int. 97:1199–1201. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cookson MS and Sarosdy MF: Management of
stage T1 superficial bladder cancer with intravesical bacillus
Calmette-Guerin therapy. J Urol. 148:797–801. 1992.PubMed/NCBI
|
|
7
|
Lamm DL, Blumenstein BA, Crissman JD, et
al: Maintenance bacillus Calmette-Guerin immunotherapy for
recurrent TA, T1 and carcinoma in situ transitional cell carcinoma
of the bladder: a randomized Southwest Oncology Group Study. J
Urol. 163:1124–1129. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lamm DL: Efficacy and safety of bacille
Calmette-Guérin immunotherapy in superficial bladder cancer. Clin
Infect Dis. 31(Suppl 3): S86–S90. 2000.
|
|
9
|
GuhaSarkar S and Banerjee R: Intravesical
drug delivery: challenges, current status, opportunities and novel
strategies. J Control Release. 148:147–159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kang MR, Yang G, Place RF, et al:
Intravesical delivery of small activating RNA formulated into lipid
nanoparticles inhibits orthotopic bladder tumor growth. Cancer Res.
72:5069–5079. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Barlow L, McKiernan JM and Benson MC:
Long-term survival outcomes with intravesical docetaxel for
recurrent nonmuscle invasive bladder cancer after previous bacillus
Calmette-Guérin therapy. J Urol. 189:834–839. 2013.
|
|
12
|
Mugabe C, Matsui Y, So AI, et al: In vivo
evaluation of mucoadhesive nanoparticulate docetaxel for
intravesical treatment of non-muscle-invasive bladder cancer. Clin
Cancer Res. 17:2788–2798. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gradishar WJ, Tjulandin S, Davidson N, et
al: Phase III trial of nanoparticle albumin-bound paclitaxel
compared with polyethylated castor oil-based paclitaxel in women
with breast cancer. J Clin Oncol. 23:7794–7803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McKiernan JM, Barlow LJ, Laudano MA, Mann
MJ, Petrylak DP and Benson MC: A phase I trial of intravesical
nanoparticle albumin-bound paclitaxel in the treatment of bacillus
Calmette-Guérin refractory nonmuscle invasive bladder cancer. J
Urol. 186:448–451. 2011.PubMed/NCBI
|
|
15
|
Buscarini M, Quek ML, Gilliam-Hegarich S,
Kasahara N and Bochner B: Adenoviral receptor expression of normal
bladder and transitional cell carcinoma of the bladder. Urol Int.
78:160–166. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
O’Donnell MA, Lilli K, Leopold C, et al:
Interim results from a national multicenter phase II trial of
combination bacillus Calmette-Guerin plus interferon alfa-2b for
superficial bladder cancer. J Urol. 172:888–893. 2004.
|
|
17
|
Yamashita M, Rosser CJ, Zhou JH, et al:
Syn3 provides high levels of intravesical adenoviral-mediated gene
transfer for gene therapy of genetically altered urothelium and
superficial bladder cancer. Cancer Gene Ther. 9:687–691. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dinney CP, Fisher MB, Navai N, et al:
Phase I trial of intravesical recombinant adenovirus mediated
interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin
failures in nonmuscle invasive bladder cancer. J Urol. 190:850–856.
2013.PubMed/NCBI
|
|
19
|
Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M,
Ganesh S, Reddy PS and Yu DC: CG0070, a conditionally replicating
granulocyte macrophage colony-stimulating factor - armed oncolytic
adenovirus for the treatment of bladder cancer. Clin Cancer Res.
12:305–313. 2006. View Article : Google Scholar
|
|
20
|
Burke JM, Lamm DL, Meng MV, et al: A first
in human phase 1 study of CG0070, a GM-CSF expressing oncolytic
adenovirus, for the treatment of nonmuscle invasive bladder cancer.
J Urol. 188:2391–2397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seager CM, Puzio-Kuter AM, Patel T, et al:
Intravesical delivery of rapamycin suppresses tumorigenesis in a
mouse model of progressive bladder cancer. Cancer Prev Res (Phila).
2:1008–1014. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Puzio-Kuter AM, Castillo-Martin M, Kinkade
CW, et al: Inactivation of p53 and Pten promotes invasive bladder
cancer. Genes Dev. 23:675–680. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang X and Godbey WT: Preclinical
evaluation of a gene therapy treatment for transitional cell
carcinoma. Cancer Gene Ther. 18:34–41. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mohammed SI, Knapp DW, Bostwick DG, et al:
Expression of cyclooxygenase-2 (COX-2) in human invasive
transitional cell carcinoma (TCC) of the urinary bladder. Cancer
Res. 59:5647–5650. 1999.PubMed/NCBI
|
|
25
|
Morales A, Chin JL and Ramsey EW:
Mycobacterial cell wall extract for treatment of carcinoma in situ
of the bladder. J Urol. 166:1633–1638. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Filion MC and Phillips NC: Therapeutic
potential of mycobacterial cell wall-DNA complexes. Expert Opin
Investig Drugs. 10:2157–2165. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Morales A, Phadke K and Steinhoff G:
Intravesical mycobacterial cell wall-DNA complex in the treatment
of carcinoma in situ of the bladder after standard intravesical
therapy has failed. J Urol. 181:1040–1045. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ahn JJ and McKiernan JM: New agents for
bacillus Calmette-Guérin-refractory bladder cancer. Urol Clin North
Am. 40:219–232. 2013.PubMed/NCBI
|
|
29
|
Miyazaki J, Kawai K, Kojima T, et al: The
liposome-incorporating cell wall skeleton of Mycobacterium
bovis bacillus Calmette-Guérin can directly enhance the
susceptibility of cancer cells to lymphokine-activated killer cells
through up-regulation of natural-killer group 2, member D ligands.
BJU Int. 108:1520–1526. 2011.PubMed/NCBI
|
|
30
|
Miyazaki J, Nishiyama H, Yano I, et al:
The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat
urinary bladder carcinoma. Anticancer Res. 31:2065–2071.
2011.PubMed/NCBI
|
|
31
|
Andrade PM, Chade DC, Borra RC, et al: The
therapeutic potential of recombinant BCG expressing the antigen
S1PT in the intravesical treatment of bladder cancer. Urol Oncol.
28:520–525. 2010. View Article : Google Scholar : PubMed/NCBI
|
